Fig. 5

DCLK1 promotes TNBC progression by activating IL6/STAT3 signaling. a Western blotting showing the decreased expression levels of phosphorylated STAT3 (Tyr705) as well as CSC-associated markers (left) and EMT-associated markers (right) in DCLK1-overexpressing MDA-MB-468 cells treated with IL-6R antagonist Tocilizumab for 24 h. b CCK8 assays to determine the sensitivity of MDA-MB-468-DCLK1-OE cells to doxorubicin after treating with Tocilizumab or DMSO (left), and the cells surviving different treatments were also showed by crystal violet (right). c Transwell assays to compare the migratory/invasive abilities of MDA-MB-468 cells with different treatment as indicated. d Western blotting showing the expression levels of phosphorylated STAT3 (Tyr705) as well as CSC-associated markers (left) and EMT-associated markers (right) in BT549 cells treated as indicated. e Flow cytometry analyzing the percentage of stem-like subpopulation CD44^high/CD24^low in BT549 cells treated as indicated. f Transwell assays to compare the migratory/invasive abilities of BT549 cells with different treatment as indicated. g Western blotting to detect the inhibitory effects of STAT3 inhibitor S31-201 to TNBC cells. H-I. Western blotting (h) and transwell assays (i) to determine the inhibitory effects of S31-201 to DCLK1-enhanced CSC traits in MDA-MB-468 cells